Compare MPLX LP (MPLX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Neurocrine Biosciences Inc — how do they compare? MPLX LP trades at $56.78 (market cap $58.11B), while Neurocrine Biosciences Inc trades at $142.25 (market cap $14.36B). The key difference: MPLX LP is far larger — about 4× Neurocrine Biosciences Inc's market cap, and MPLX LP pays a 7.51% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MPLX | NBIX | |
|---|---|---|
Market Cap | $58.11B | $14.36B |
Volume | 687,483 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $60.51 | $185.50 |
52-Week Low | $47.80 | $123.10 |
Enterprise Value | $83.22B | $14.37B |
Dividend Yield | 7.51% | — |
Typical Hold Time | — | 23 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.86, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and dividend payments. Technical indicators show mixed signals with RSI neutral but ADX suggesting selling pressure.
MPLX offers value with a 12.33 P/E ratio and strong profitability metrics, but faces headwinds from recent earnings misses and energy market volatility. The stock presents income appeal with dividend coverage, though investors should monitor execution on future earnings and energy price sensitivity.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
